WHAT WE DO:
Right cargo,
right vehicle
Gramics Bio is engineering a new class of gene therapy that combines the durability and dosing frequency of viral vectors with the safety, manufacturability and scalability of LNPs.
We enable safe, cell-type-specific delivery of therapeutic DNA with long-lasting effects from a single dose and the ability to re-dose if needed.
WHAT MAKES US DIFFERENT:
Cargo engineering
We work with proven delivery vehicles.
Our technology slots into existing LNP delivery vehicles with established safety, biodistribution, and formulation data. No need to develop new chemistries or reformulate vehicles.
We build intelligence into the cargo.
By programming specificity into the DNA itself, we create a generalizable, modular solution that can combine with different delivery vehicles and therapeutic modalities.
We avoid complex, costly manufacturing.
Our LNP-based approach benefits from low-cost manufacturing and scalability.
HOW WE DO IT:
Design, test, optimise
We integrate synthetic biology, AI/ML, high-throughput screening and automation to rationally design, test, and optimize synthetic DNA sequences.
Our sequences are designed to drive nuclear entry and therapeutic gene expression on a cell-type and cell-state specific basis.
WHY IT MATTERS:
Patients are waiting
We're starting with cystic fibrosis (CF) where no gene therapy is currently available. Beyond CF, our platform has the potential to unlock a new wave of transformational therapeutics for monogenic diseases.
Gramics Bio was born from urgency - from the recognition that despite remarkable advances in genetic medicine, too many patients are still left behind. We're building a platform to change that, combining bold scientific ambition with deep patient insight to create gene therapies that work where they're needed most.
OUR FOUNDERS:
Founded by a scientist and a patient
Our team combines world-leading scientific expertise with deep patient insight and a track record in biotech and venture building.
Oli Rayner
Co-Founder and CEO
Oli was born with cystic fibrosis and told he wouldn't live beyond childhood. Rather than accept that fate, he's attacked the disease from every angle: as a patient, advocate, investor, and founder. Oli previously led Business Development in Europe for the Cystic Fibrosis Foundation, building biopharma partnerships focused on nucleic acid therapeutics. He developed and launched the UK's CF clinical trial network and played a pivotal role in securing NHS funding for CFTR modulators. Before moving into biomedical innovation, he worked in investment banking and venture investing.
Dr Alice Preston
Co-Founder and CSO
Alice is a scientist with world-leading expertise in DNA regulation and expression, with a PhD in cell and gene therapy for Duchenne Muscular Dystrophy (UCL/Great Ormond Street Hospital) and 8 years as a postdoc at the University of Oxford, studying how DNA sequences bind to nuclear proteins to drive gene expression. Alice was previously Principal Scientist at Ochre Bio, developing RNA-based liver therapeutics, and she was co-founder and CSO at Prismea, a software-based bioinformatics startup, developing custom computational pipelines for biotechs.
BOARD AND ADVISORS:
Powerful perspective
Dr Francesca Crawford
Board Member
Fran was Founder CEO of ViaNautis. She is a serial biotech company builder.
Dr Enrique Lin Shao
Board Observer
Enrique is Head of Search and Evaluation at the Cystic Fibrosis Foundation.
OUR INVESTORS:
Strategic capital
CONTACT US:
Oxford, London, Online
Lab
BioInnovation Hub
Gipsy Lane
Headington
Oxford
OX3 0BP
Registered Office
First Floor
85 Great Portland Street
London
W1W 7LT
